Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Overlap connective tissue disease syndromes.Autoimmun Rev. 2013; 12: 363-373
- Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.J Rheumatol. 2010; 37: 1488-1501
- Articular involvement in systemic sclerosis.Rheumatology. 2012; 51: 1347-1356
- Inflammatory arthritis in systemic sclerosis: what to do?.J Scleroderma Relat Disord. 2019; 4: 3-16
- Daily activities and hand function in women with scleroderma.Scand J Rheumatol. 2004; 33: 102-107
- The articular manifestations of progressive systemic sclerosis (scleroderma).Ann Rheum Dis. 1982; 41: 147-152
- Musculoskeletal manifestations of systemic sclerosis.Rheum Dis Clin North Am. 2015; 41: 507-518
- Systemic sclerosis at the crossroad of polyautoimmunity.Autoimmun Rev. 2013; 12: 1052-1057
- Radiological hand involvement in systemic sclerosis.Ann Rheum Dis. 2006; 65: 1088-1092
- Anti-cyclic citrullinated peptide antibody in systemic sclerosis.Clin Exp Rheumatol. 2008; 26: 542-547
- Clinical and serological hallmarks of systemic sclerosis overlap syndromes.J Rheumatol. 2011; 38: 2406-2409
- Anti-cyclic citrullinated peptide antibodies in scleroderma patients.Clin Rheumatol. 2012; 31: 877-880
- Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis.Rheumatology. 2010; 49: 2135-2139
- Erosive arthritis autoantibodies in systemic sclerosis.Semin Arthritis Rheum. 2022; 52: 151947
- Autoantibodies in systemic sclerosis.Semin Arthritis Rheum. 2005; 35: 35-42
- Imaging of Scleroderma.Rheum Dis Clin North Am. 2013; 39: 515-546
- Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings.Arthritis Care Res. 2012; 64: 1244-1249
- Magnetic resonance imaging versus musculoskeletal ultrasonography in detecting inflammatory arthropathy in systemic sclerosis patients with hand arthralgia.Rheumatol Int. 2013; 33: 1961-1966
- Validation of disease activity indices using the 28 joint counts in systemic sclerosis.Rheumatology. 2016; 55: 1849-1858
- Management of systemic sclerosis: the first five years.Curr Opin Rheumatol. 2020; 32: 228-237
- French recommendations for the management of systemic sclerosis.Orphanet J Rare Dis. 2021; 16
- Treatment algorithms for systemic sclerosis according to experts.Arthritis Rheumatol. 2018; 70: 1820-1828
- Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.Ann Rheum Dis. 2013; 72: 1217-1220
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.Ann Rheum Dis. 2019; 78: 979-987
- Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience.Semin Arthritis Rheum. 2020; 50: 1489-1493
- Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial.Arthritis Rheumatol. 2020; 72: 125-136
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med. 2020; 8: 963-974
- Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.Lancet Rheumatol. 2021; 3: e489-e497
- Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: a case series study and review of the literature.Int J Rheum Dis. 2022; 25: 755-768
- Biologic therapy for systemic sclerosis: a systematic review.J Rheumatol. 2011; 38: 289-296
- Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.Semin Arthritis Rheum. 2011; 41: 256-264
- Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?.Drug Des Devel Ther. 2019; 13: 2111-2125
- Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.Rheumatol Int. 2021; 41: 1743-1753
- Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: A pilot study.Ann Rheum Dis. 2007; 66: 977-979
- A comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc.Best Pract Res Clin Rheumatol. 2021; 35
- The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review.Rheumatol Adv Pract. 2019; 3: rkz044
Article info
Publication history
Published online: March 01, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
